With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...
Stifel Nicolaus analyst Alex Thompson CFA has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...
Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. The company ...
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) were down 3.4% during trading on Tuesday . The stock traded as low as $18.77 and last traded at $19.01. Approximately 81,134 ...
The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The ...
The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The US$ ...
Hosted on MSN22d
Wells Fargo Downgrades Viridian Therapeutics (VRDN)Fintel reports that on December 19, 2024, Wells Fargo downgraded their outlook for Viridian Therapeutics (NasdaqCM:VRDN) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 121.47% ...
Viridian Therapeutics (NASDAQ:VRDN) reported positive topline results from the THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (‘TED’) patients. The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback